Optimizing Bispecific Therapy in Myeloma: Choosing the Right Time for Treatment | EHA 2026

When is the best time to use bispecific antibodies in the treatment of multiple myeloma? At EHA 2026, Jens Hillengass explores one of the most important questions facing clinicians today: how to optimally incorporate bispecific antibodies into the myeloma treatment journey. If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.